Fig. 6

Application of MSC-related prognostic model in therapy cohorts. A Kaplan–Meier analysis of low- and high-risk score in GSE19061. B The risk scores of different response groups of GSE19061. C The proportion of patients with response to anti-PD-1 immunotherapy in different risk groups. D Expression of pro-angiogenic factors in the TCGA cohort. E Expression of pro-angiogenic factors in GSE140082. F Overall survival in GSE140082 with different treatments. High: high-risk group; Low: low-risk group. Standard treatment: carboplatin plus paclitaxel chemotherapy. Bevacizumab treatment: carboplatin plus paclitaxel chemotherapy plus Bevacizumab. CR complete response, PR partial response, SD stable disease, PD progressive disease